Recent Investment Analysts’ Ratings Updates for BridgeBio Pharma (BBIO)

BridgeBio Pharma (NASDAQ: BBIO) recently received a number of ratings updates from brokerages and research firms:

• 10/7/2026 – BridgeBio Pharma had its price target lowered by Barclays PLC from $157.00 to $156.00. They now have an “overweight” rating on the stock.
• 10/6/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by HC Wainwright.
• 10/5/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 10/5/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by TD Cowen.
• 10/5/2026 – BridgeBio Pharma had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/25/2026 – BridgeBio Pharma was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 9/10/2026 – BridgeBio Pharma was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 9/10/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
• 9/2/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by UBS Group AG.
• 9/2/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
• 9/1/2026 – BridgeBio Pharma had its price target raised by Mizuho from $96.00 to $110.00. They now have an “outperform” rating on the stock.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $80.06, for a total value of $160,120.00. Following the completion of the sale, the chief accounting officer directly owned 127,401 shares of the company’s stock, valued at $10,199,724.06. This trade represents a 1.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $69.08, for a total value of $690,800.00. Following the completion of the sale, the chief executive officer directly owned 495,686 shares of the company’s stock, valued at $34,241,988.88. This trade represents a 1.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 56,980 shares of company stock valued at $4,578,119. 14.23% of the stock is owned by company insiders.

BridgeBio Pharma, Inc is a biotechnology company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company uses its drug discovery and development platform to advance therapies across areas including rare diseases, genetic disorders and precision oncology, with programs designed to address the underlying biological causes of disease.

BridgeBio operates through a collection of subsidiary companies and development programs. Its portfolio has included therapies for cardiovascular, endocrine, neurological and oncological conditions.